retatrutide clinical trial parkinson Eli Lilly infiltrates anti-obesity market as Phase III for begins retatrutide parkinson's disease clinical trial

Before making a final choice, consult a healthcare provider

According to incomplete statistics, sales of Novo Nordisk's semaglutide have been soaring year after year, with 2023 sales surpassing $21.2 billion, making it the first GLP-1 drug to join the "billion-dollar club." Its market position is quickly catching up with Merck's Keytruda, and it has the potential to become the next "blockbuster" drug

Now Approved for Weight Management For many individuals, weight loss is a significant challenge

doi: 10.2174/157340313805076322 150 Report TP

It is the dose that supports meaningful progress while allowing the patient to eat, hydrate, function, preserve muscle, and maintain follow-up

Studies show that you can lose an average of 15% of your body weight over about 68 weeks